COMP <GO>
ALEC vs IRLA // GROSS PROFIT MARGIN
Alector Inc. (NASDAQ) VS. IRulya Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ALEC 2
— IRLA 1
■ METRIC PARITY
LAST: $2.24 (-0.44%) • MKT CAP: $332.1M
gross-margins
—
LAST: $31.62 (-4.05%) • MKT CAP: $342.8M
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALEC VS. IRLA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALEC | IRLA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -12.19% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 1/9 | +1.00 | ALEC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.4 | 52.5 | +7.88 | ALEC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $332.1M | $342.8M | -$10.7M | IRLA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALEC REV | IRLA REV | ALEC GROSS % | IRLA GROSS % | ALEC FCF | IRLA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $21.0M | $0 | — | — | -$184.1M | -$41.8M |
| FY 2024 | $100.6M | $0 | — | — | -$231.2M | -$32.2M |
| FY 2023 | $97.1M | $0 | — | — | -$184.2M | -$18.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALEC // BETA —
IRLA // BETA —